Pharvaris N.V. (NASDAQ:PHVS) Receives $36.20 Average Target Price from Analysts

Shares of Pharvaris N.V. (NASDAQ:PHVS) have been given an average recommendation of “Buy” by the five analysts that are currently covering the company, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $36.20.

Several equities research analysts have recently commented on the company. Cantor Fitzgerald lowered their target price on Pharvaris from $28.00 to $25.00 and set an “overweight” rating for the company in a research note on Wednesday, May 14th. Wedbush reiterated an “outperform” rating and issued a $27.00 price target on shares of Pharvaris in a report on Thursday, June 5th. Finally, Guggenheim initiated coverage on Pharvaris in a research report on Wednesday, June 11th. They issued a “buy” rating and a $32.00 price objective for the company.

Pharvaris Trading Up 0.6%

Shares of NASDAQ PHVS opened at $20.00 on Thursday. Pharvaris has a 1-year low of $11.51 and a 1-year high of $26.33. The company has a 50-day moving average of $18.74 and a two-hundred day moving average of $17.04. The company has a market cap of $1.05 billion, a PE ratio of -6.64 and a beta of -2.81.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.09). As a group, equities research analysts forecast that Pharvaris will post -2.71 earnings per share for the current year.

Institutional Trading of Pharvaris

Several institutional investors and hedge funds have recently made changes to their positions in the business. Soleus Capital Management L.P. boosted its position in shares of Pharvaris by 36.2% in the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company’s stock worth $15,617,000 after purchasing an additional 216,483 shares during the last quarter. FMR LLC lifted its stake in Pharvaris by 3.6% in the fourth quarter. FMR LLC now owns 5,395,370 shares of the company’s stock valued at $103,429,000 after buying an additional 189,714 shares during the period. Octagon Capital Advisors LP boosted its holdings in Pharvaris by 25.4% during the fourth quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company’s stock worth $14,914,000 after buying an additional 157,530 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in Pharvaris by 36.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company’s stock worth $8,510,000 after buying an additional 118,408 shares during the last quarter. Finally, Northern Trust Corp grew its position in shares of Pharvaris by 483.9% during the 4th quarter. Northern Trust Corp now owns 91,932 shares of the company’s stock worth $1,762,000 after buying an additional 76,188 shares during the period.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.